This is an aggregated industry headline. Read the full story at FierceBiotech →
Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling
With a panel of outside experts set to weigh in Thursday-and with a refusal-to-file fiasco with the FDA just barely in the rearview-Moderna and its contender for the United States' first mRNA-based influenza vaccine are heading into a critical test this week.
By FierceBiotech
· Jun 17, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest q…
The WeekBriefing
Starting next month, Medicare will offer weight loss drug coverage through a temporary program that observers …
The WeekBioPharma Dive ↗
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing "anti…